Vaginal contraception: a roadmap to women's reproductive autonomy-a narrative review


  • Naina Kumar Department of Obstetrics and Gynecology, All India Institute of Medical Sciences, Bibinagar, Hyderabad, Telangana, India



Contraception, Estrogen, Progestogen, Sexually transmitted infections, Vaginal ring


The right to contraception information and services is one of the essential rights of every woman that guarantees access to safe, acceptable, available, and good-quality contraceptives. Contraceptive vaginal rings are a form of modern contraceptive that is user-friendly, effective, and safe to use. The present review briefs about the contraceptive vaginal ring, its composition, mechanism of action, advantages, disadvantages, and newer development of rings with added benefits. Methodology: The recent literature till December 2021 was searched from the various governmental, and non-governmental agencies including WHO, UNFPA, UNDP, UNDESA, Committee on the Rights of the Child, FDA, and many English peer-reviewed journals, including PubMed database, the regional portal of virtual health library, and scientific electronic library online using following search terms “modern contraception”, “contraceptive vaginal ring”, and “newer vaginal rings”. The contraceptive vaginal ring has emerged as an effective, safe, self-administered form of modern contraceptive, with better cycle control, compliance, and continuation rates.


UNFPA. Briefing paper. The right to contraceptive information and services for women and adolescents. 2010 Center for Reproductive Rights. Available at: Accessed on 2 September 2023.

Committee on the Rights of the Child, General Comment 4: Adolescent health and development in the context of the Convention on the Rights of the Child, para. 28, U.N. Doc. CRC/GC/2003/41 July 2003. Available at: Accessed on 2 September 2023.

Kebede A, Abaya SG, Merdassa E, Bekuma TT. Factors affecting demand for modern contraceptives among currently married reproductive age women in rural Kebeles of Nunu Kumba district, Oromia, Ethiopia. Contracept Reprod Med. 2019;4:21.

Riley T, Sully E, Ahmed Z, Biddlecom A. Estimates of the potential impact of the COVID-19 pandemic on sexual and reproductive health in low- and middle-income countries. Int Perspect Sex Reprod Health. 2020;46:73-6.

Kantorová V, Wheldon MC, Ueffing P, Dasgupta ANZ. Estimating progress towards meeting women's contraceptive needs in 185 countries: A Bayesian hierarchical modelling study. PLoS Med. 2020;17(2):1003026.

United Nations. Department of Economic and Social Affairs, Population Division. Family Planning and the 2030 Agenda for Sustainable Development. New York: United Nations. Accessed on 2 September 2023.

UNDP. Costing the Three Transformative Results. 2019. Available at: Accessed on 2 September 2023.

Kumar N. COVID 19 era: a beginning of upsurge in unwanted pregnancies, unmet need for contraception and other women related issues. Eur J Contracept Reprod Health Care. 2020;25(4):323-5.

United Nations, Department of Economic and Social Affairs, Population Division (2019). Contraceptive Use by Method 2019: Data Booklet (ST/ESA/SER.A/435). Available at: Accessed on 2 September 2023.

Tetui M, Baroudi M, Ssekamatte T, Birabwa C, Kibira SP, Atuyambe L, et al. Total demand, use and unmet need for modern contraceptives among women living in informal settlements in Kira Municipality, Wakiso District, Uganda. Implications for Urban Health. Front Glob Womens Health. 2021;2:655413.

Ethiopian Public Health Institute (EPHI) [Ethiopia] and ICF. 2021. Ethiopia mini demographic and health survey 2019: Final report. Rockville, Maryland, USA: EPHI and ICF.

Brache V, Payán LJ, Faundes A. Current status of contraceptive vaginal rings. Contraception. 2013;87(3):264-72.

Mishell DR, Lumkin ME. Contraceptive effect of varying dosages of progestogen in silastic vaginal rings. Fertil Steril. 1970;21(2):99-103.

Temmerman M. A new woman-controlled contraceptive vaginal ring: a global step forward. Lancet Glob Health. 2019;7(8):986-7.

FDA approves NuvaRing contraceptive implant. J Gend Specif Med. 2002;5(2):6.

Roumen FJ. Review of the combined contraceptive vaginal ring, NuvaRing. Ther Clin Risk Manag. 2008;4(2):441-51.

Wieder DR, Pattimakiel L. Examining the efficacy, safety, and patient acceptability of the combined contraceptive vaginal ring (NuvaRing). Int J Womens Health. 2010;2:401-9.

Brache V, Faundes A. Contraceptive vaginal rings: a review. Contraception. 2010;82(5):418-27.

Monteiro I, Guazzelli CF, Bahamondes L. Advances in contraceptive vaginal rings: what does the future hold? Expert Opin Pharmacother. 2018;19(15):1685-91.

Delvaux T, Jespers V, Benova L, van de Wijgert J. Acceptability and satisfaction of contraceptive vaginal rings in clinical studies: a systematic review and narrative synthesis. Front Glob Womens Health. 2021;2:799963.

U.S. Food and Drug Administration. FDA News Release. FDA approves new vaginal ring for one year of birth control, 10th August 2018. Available at: Accessed on 2 September 2023.

Archer DF, Merkatz RB, Bahamondes L, Westhoff CL, Darney P, Apter D, et al. Efficacy of the 1-year (13-cycle) segesterone acetate and ethinylestradiol contraceptive vaginal system: results of two multicentre, open-label, single-arm, phase 3 trials. Lancet Glob Health. 2019;7(8):1054-64.

Kumar N, Koide SS, Tsong Y, Sundaram K. Nestorone: a progestin with a unique pharmacological profile. Steroids. 2000;65(10-11):629-36.

Kumar N, Fagart J, Liere P, Mitchell SJ, Knibb AR, Petit-Topin I, et al. Nestorone® as a novel progestin for nonoral contraception: structure-activity relationships and brain metabolism studies. Endocrinology. 2017;158(1):170-82.

Nelson AL. Comprehensive overview of the recently FDA-approved contraceptive vaginal ring releasing segesterone acetate and ethinylestradiol: A new year-long, patient controlled, reversible birth control method. Expert Rev Clin Pharmacol. 2019;12(10):953-63.

Gemzell-Danielsson K, Sitruk-Ware R, Creinin MD, Thomas M, Barnhart KT, Creasy G, et al. Segesterone acetate/ethinyl estradiol 12-month contraceptive vaginal system safety evaluation. Contraception. 2019;99(6):323-8.

Gruber CJ. The combined contraceptive vaginal ring (NuvaRing): evaluation of the clinical and pharmacological evidence. Womens Health (Lond). 2006;2(3):351-6.

Medical Eligibility Criteria for Contraceptive Use. 5th ed. Geneva: World Health Organization; 2015.

Carr SL, Gaffield ME, Dragoman MV, Phillips S. Safety of the progesterone-releasing vaginal ring (PVR) among lactating women: A systematic review. Contraception. 2016;94(3):253-61.

Nath A, Sitruk-Ware R. Progesterone vaginal ring for contraceptive use during lactation. Contraception. 2010;82(5):428-34.

Massai R, Díaz S, Jackanicz T, Croxatto HB. Vaginal rings for contraception in lactating women. Steroids. 2000;65(10-11):703-7.

EMEA Committee for Veterinary Medicinal Products Progesterone: Summary Report. Available at: (1999). Accessed on 2 September 2023.

Nave R, Höchel J, Mellinger U, Kohnke A, Elliesen J, Schmitz H. Pearl Index study with levonorgestrel-releasing intravaginal rings: using pharmacokinetic results to investigate treatment compliance as a potential contributor for contraceptive failure. Hum Reprod. 2020;35(11):2515-23.

Massai R, Miranda P, Valdés P, Lavín P, Zepeda A, Casado ME, et al. Preregistration study on the safety and contraceptive efficacy of a progesterone-releasing vaginal ring in Chilean nursing women. Contraception. 1999;60(1):9-14.

Bashi YH, McCoy CF, Murphy DJ, Boyd P, Spence P, Kleinbeck K, et al. Towards a dapivirine and levonorgestrel multipurpose vaginal ring: Investigations into the reaction between levonorgestrel and addition-cure silicone elastomers. Int J Pharm. 2019;569:118574.

Thurman AR, Schwartz JL, Brache V, Clark MR, McCormick T, Chandra N, et al. Randomized, placebo-controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women. PLoS One. 2018;13(6):0199778.

World Health Organization. WHO recommends the dapivirine vaginal ring as a new choice for HIV prevention for women at substantial risk of HIV infection. 26 January, 2021. Available at: Accessed on 2 September 2023.

Garg AB, Nuttall J, Romano J. The future of HIV microbicides: challenges and opportunities. Antivir Chem Chemother. 2009;19(4):143-50.

Nuttall JP, Thake DC, Lewis MG, Ferkany JW, Romano JW, Mitchnick MA. Concentrations of dapivirine in the rhesus macaque and rabbit following once daily intravaginal administration of a gel formulation of [14C] dapivirine for 7 days. Antimicrob Agents Chemother. 2008;52(3):909-14.

Balkus JE, Palanee-Phillips T, Reddy K, Siva S, Harkoo I, Nakabiito C, et al. Brief report: dapivirine vaginal ring use does not diminish the effectiveness of hormonal contraception. J Acquir Immune Defic Syndr. 2017;76(2):47-51.

Ballagh SA. Vaginal rings for menopausal symptom relief. Drugs Aging. 2004;21(12):757-66.

Krause M, Wheeler TL, Snyder TE, Richter HE. Local effects of vaginally administered estrogen therapy: a review. J Pelvic Med Surg. 2009;15(3):105-14.

Edwardson J, Jamshidi R. The contraceptive vaginal ring. Semin Reprod Med. 2010;28(2):133-9.

Roumen FJ, Mishell DR. The contraceptive vaginal ring, NuvaRing(®), a decade after its introduction. Eur J Contracept Reprod Health Care. 2012;17(6):415-27.






Review Articles